Numerous clinical trials spanning Early Phase 1 to Phase 3 evaluate oral or parenteral azacitidine, as monotherapy or combined with targeted agents, for hematologic conditions such as acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, and peripheral T-cell lymphoma in newly diagnosed or relapsed/refractory patients. Conducted by academic medical centers, cooperative research organizations, and pharmaceutical industry sponsors, these studies encompass active, recruiting, completed, and terminated protocols.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03013998 | RECRUITING | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia |
Beat AML, LLC |
2016-11 | PHASE2; PHASE3 |
| NCT07007312 | RECRUITING | Acute Myeloid Leukemia (AML) |
Kura Oncology, Inc. |
2025-09-26 | PHASE3 |
| NCT04062266 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia in Remission; FLT3 Gene Mutation; Hematologic and Lymphocytic Disorder; Acute Myeloid Leukemia; Minimal Residual Disease Persistence; Therapy-Related Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2019-09-13 | PHASE2 |
| NCT06454409 | SUSPENDED | Myelodysplastic Syndrome/Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome |
City of Hope Medical Center |
2025-05-21 | PHASE1 |
| NCT07082452 | NOT_YET_RECRUITING | Leukemia, B-Cell, Chronic; Leukemia |
Gustave Roussy, Cancer Campus, Grand Paris |
2025-09 | PHASE3 |
| NCT05904106 | RECRUITING | Acute Myeloid Leukemia |
Technische Universität Dresden |
2024-04-07 | PHASE2 |
| NCT07463768 | NOT_YET_RECRUITING | Acute Myeloid Leukemia |
French Innovative Leukemia Organisation |
2026-09 | PHASE2 |
| NCT07434492 | RECRUITING | Cerebral Palsy |
Shirley Ryan AbilityLab |
2026-05-28 | PHASE2 |
| NCT05442216 | RECRUITING | Acute Myeloid Leukemia |
Joshua Zeidner |
2024-05-01 | PHASE2 |
| NCT07645469 | RECRUITING | Acute Myeloid Leukemia |
Fred Hutchinson Cancer Center |
2026-09-01 | PHASE1 |
| NCT07320235 | RECRUITING | Relapsed Acute Myeloid Leukemia |
Douglas Tremblay |
2026-01-02 | PHASE1 |
| NCT07672262 | RECRUITING | Acute Myeloid Leukemia; Intermediate Risk Acute Myeloid Leukemia; Consolidation Therapy |
The First Affiliated Hospital of Soochow University |
2026-06-01 | PHASE2 |
| NCT07562568 | NOT_YET_RECRUITING | Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; MDS; Transplantation, Stem Cell; Conditioning Therapy; SHR2554; Azacytidine |
The First Affiliated Hospital of Soochow University |
2026-06 | PHASE2 |
| NCT07238686 | RECRUITING | Myelodysplastic Syndromes |
Beijing 302 Hospital |
2025-06-20 | PHASE2 |
| NCT07078591 | RECRUITING | Acute Myeloid Leukemia |
Beijing 302 Hospital |
2025-06-20 | PHASE2 |
| NCT07770698 | NOT_YET_RECRUITING | Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; B-cell Acute Lymphoblastic Leukemia; Pediatric Cancer; Pediatric ALL, Relapsed; Pediatric ALL; Pediatric ALL, B Cell; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Pediatric AML; R/R AML; R/R B-cell ALL |
BeOne Medicines |
2026-10 | PHASE1; PHASE2 |
| NCT05735184 | RECRUITING | Acute Myeloid Leukemia; Mixed Lineage Leukemia Gene Mutation; Refractory AML; AML With Mutated NPM1; Acute Myeloid Leukemia Recurrent; Acute Myeloid Leukemia, in Relapse; NPM1 Mutation; KMT2Ar; Myeloid Sarcoma; Nucleophosmin 1-mutated Acute Myeloid Leukemia |
Kura Oncology, Inc. |
2023-07-18 | PHASE1 |
| NCT07276698 | NOT_YET_RECRUITING | NK T-Cell Lymphoma |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2025-12-30 | PHASE2 |
| NCT06652438 | RECRUITING | Acute Myeloid Leukemia, Adult |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2025-05-05 | PHASE3 |
| NCT07651176 | ENROLLING_BY_INVITATION | Acute Myeloid Leukemia; Lisaftoclax |
First Affiliated Hospital of Zhejiang University |
2026-03-01 | PHASE2; PHASE3 |
| NCT05367401 | WITHDRAWN | Myelodysplastic Syndromes; Acute Myeloid Leukemia |
Novartis Pharmaceuticals |
2024-12-20 | PHASE1; PHASE2 |
| NCT07755202 | NOT_YET_RECRUITING | Acute Myeloid Leukemia; AML With FLT3 Mutation |
Florian Kuchenbauer |
2026-09-01 | PHASE2 |
| NCT07521124 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML) in Remission |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2026-06-01 | |
| NCT07542912 | NOT_YET_RECRUITING | Complete Remission Rate， CRR; Progression Free Survival; Overall Survival; Adverse Event; Duration of Response |
Sun Yat-sen University |
2026-06-01 | |
| NCT06641414 | RECRUITING | Higher-risk Myelodysplastic Syndrome |
Ascentage Pharma Group Inc. |
2025-01-22 | PHASE3 |
| NCT07575412 | NOT_YET_RECRUITING | Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; MDS; Transplantation, Stem Cell; Conditioning Therapy; SHR2554; Azacytidine |
The First Affiliated Hospital of Soochow University |
2026-06 | PHASE2 |
| NCT07635485 | NOT_YET_RECRUITING | Hypoplastic Acute Myeloid Leukemia; Secondary AML (Adult) |
The First Affiliated Hospital of Soochow University |
2026-06-01 | |
| NCT06317649 | RECRUITING | Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2024-09-27 | PHASE2 |
| NCT06696183 | RECRUITING | AML - Acute Myeloid Leukemia |
Technische Universität Dresden |
2025-04-25 | PHASE2 |
| NCT06782542 | RECRUITING | Acute Myeloid Leukemia; IDH1 Mutation |
Justin Watts, MD |
2026-03-31 | PHASE2 |
| NCT07177079 | RECRUITING | Acute Myeloid Leukemia |
Kittika Poonsombudlert |
2026-03-18 | PHASE1 |
| NCT07148947 | RECRUITING | Accelerated Phase Myeloproliferative Neoplasm; Blast Phase Myeloproliferative Neoplasm |
University of Washington |
2026-03-02 | PHASE2 |
| NCT07646821 | NOT_YET_RECRUITING | Ropeginterferon; Alfa-2b; Azacitidine; MDS/AML |
M.D. Anderson Cancer Center |
2026-11-27 | PHASE1; PHASE2 |
| NCT07075016 | RECRUITING | Acute Myeloid Leukemia |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2025-08-05 | PHASE3 |
| NCT06557421 | RECRUITING | Acute Myeloid Leukemia |
Institut Paoli-Calmettes |
2026-02-04 | PHASE2 |
| NCT06180863 | WITHDRAWN | Acute Myeloid Leukemia |
Yale University |
2023-11 | PHASE2 |
| NCT04140487 | RECRUITING | Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic/Myeloproliferative Neoplasm |
M.D. Anderson Cancer Center |
2019-12-17 | PHASE1; PHASE2 |
| NCT07679334 | NOT_YET_RECRUITING | Myeloproliferative Neoplasm |
Roswell Park Cancer Institute |
2026-09-01 | PHASE1 |
| NCT04501120 | RECRUITING | Relapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy |
Ascentage Pharma Group Inc. |
2020-09-28 | PHASE1; PHASE2 |
| NCT06664879 | ACTIVE_NOT_RECRUITING | AML |
M.D. Anderson Cancer Center |
2024-12-30 | PHASE1; PHASE2 |
| NCT07746245 | NOT_YET_RECRUITING | Peripheral T-Cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2026-08-01 | PHASE2 |
| NCT07735117 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS) |
Ruijin Hospital |
2026-07-30 | PHASE3 |
| NCT07392814 | NOT_YET_RECRUITING | Leukemia Acute Myeloid - AML |
Nantes University Hospital |
2026-03-10 | PHASE1 |
| NCT05317000 | RECRUITING | Squamous Cell Carcinoma of Head and Neck |
Barbara Burtness |
2023-03-23 | PHASE2 |
| NCT07642453 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML) |
Hematology department of the 920th hospital |
2026-06-01 | PHASE2 |
| NCT05404906 | RECRUITING | Acute Myeloid Leukemia (AML) in Remission |
The First Affiliated Hospital of Soochow University |
2022-06-25 | PHASE2; PHASE3 |
| NCT06668558 | RECRUITING | Acute Myeloid Leukemia |
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias |
2024-12-16 | PHASE2 |
| NCT07471841 | RECRUITING | IDH1 Mutation; Relapsed / Refractory AML |
Timothy Pardee |
2026-09 | PHASE2 |
| NCT07046182 | ACTIVE_NOT_RECRUITING | Angioimmunoblastic T-cell Lymphoma (AITL) |
Zhengzhou University |
2023-10-21 | PHASE4 |
| NCT07091006 | NOT_YET_RECRUITING | Relapse Leukemia |
Ruijin Hospital |
2025-08-01 | PHASE2 |
| NCT07283900 | RECRUITING | Myelodysplastic Syndromes |
Prajwal Dhakal |
2026-03-11 | PHASE2 |
| NCT06598332 | WITHDRAWN | Graft-Versus-Host Disease(GVHD) |
Baylor College of Medicine |
2025-08 | EARLY_PHASE1 |
| NCT07514832 | RECRUITING | AML (Acute Myeloid Leukemia) |
Beijing 302 Hospital |
2026-04-15 | PHASE2 |
| NCT07018752 | RECRUITING | Peripheral T Cells Lymphoma (PTCL) |
The Lymphoma Academic Research Organisation |
2025-08-20 | PHASE1; PHASE2 |
| NCT07507825 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML) |
First People's Hospital of Hangzhou |
2026-03-31 | PHASE2 |
| NCT07071155 | RECRUITING | Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes; Myeloproliferative Overlap Neoplasms; Chronic Neutrophilic Leukemia |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2026-03-19 | EARLY_PHASE1 |
| NCT06014489 | RECRUITING | AML, Adult |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2024-01-17 | PHASE2 |
| NCT07404332 | RECRUITING | Solid Tumor; Locally Advanced Solid Tumor; Metastatic Tumor |
Mohammed Milhem |
2026-02-11 | PHASE1 |
| NCT03850418 | RECRUITING | Myeloid Malignancy |
Henry Ford Health System |
2019-07-01 | PHASE2 |
| NCT06456463 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
Stemline Therapeutics, Inc. |
2025-01-14 | PHASE2 |
| NCT07389616 | RECRUITING | Peripheral T Cell Lymphoma |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2026-02-01 | PHASE2; PHASE3 |
| NCT07407660 | NOT_YET_RECRUITING | Acute Myeloid Leukemia |
Peking University People's Hospital |
2026-02-01 | PHASE3 |
| NCT07439211 | RECRUITING | Leukemia, Myeloid; Leukemia; Acute Myeloid Leukemia; Refractory Leukemia |
Jacqueline Garcia, MD |
2026-04-13 | PHASE1 |
| NCT07372352 | RECRUITING | Peripheral T Cells Lymphoma (PTCL) |
The First Affiliated Hospital of Soochow University |
2026-01-15 | PHASE2 |
| NCT07392242 | RECRUITING | Acute Myeloid Leukemia |
Memorial Sloan Kettering Cancer Center |
2026-01-27 | PHASE2 |
| NCT07548983 | RECRUITING | Acute Myeloid Leukemia |
OHSU Knight Cancer Institute |
2026-04-21 | PHASE1 |
| NCT05365035 | RECRUITING | Myelodysplastic Syndromes; Myeloproliferative Chronic Myelomonocytic Leukemia |
M.D. Anderson Cancer Center |
2022-09-23 | PHASE2 |
| NCT07573670 | NOT_YET_RECRUITING | Newly Diagnosed Mixed Phenotype Acute Leukemia |
The First Affiliated Hospital of Soochow University |
2026-05-01 | PHASE2 |
| NCT05554393 | RECRUITING | Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2024-09-13 | PHASE2 |
| NCT06386302 | RECRUITING | AML; Acute Myeloid Leukemia |
Institute of Hematology & Blood Diseases Hospital, China |
2024-08-05 | |
| NCT07304011 | RECRUITING | Acute Myeloid Leukemia |
University of California, Davis |
2025-12-17 | PHASE2 |
| NCT05678933 | ENROLLING_BY_INVITATION | Peripheral T-cell Lymphoma Targeted Therapy |
Tianjin Medical University Cancer Institute and Hospital |
2023-01-01 | PHASE3 |
| NCT06744556 | ACTIVE_NOT_RECRUITING | AML |
Institute of Hematology & Blood Diseases Hospital, China |
2025-01-21 | PHASE2 |
| NCT07255872 | NOT_YET_RECRUITING | Acute Myeloid Leukemia |
Sichuan Baili Pharmaceutical Co., Ltd. |
2026-03 | PHASE2; PHASE3 |
| NCT04581512 | RECRUITING | Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes |
Ellipses Pharma |
2020-11-02 | PHASE1; PHASE2 |
| NCT05586074 | RECRUITING | Leukemia, Acute Myeloid (AML) |
Sunshine Lake Pharma Co., Ltd. |
2023-03-03 | PHASE3 |
| NCT06465953 | RECRUITING | Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS); Myelodysplastic Syndromes (MDS) |
Institut de Recherches Internationales Servier |
2024-12-03 | PHASE3 |
| NCT04256317 | RECRUITING | Myelodysplastic Syndromes; Acute Myeloid Leukemia; Myelodysplastic Syndrome/Neoplasm; Chronic Myelomonocytic Leukemia |
Taiho Oncology, Inc. |
2020-05-21 | PHASE2; PHASE3 |
| NCT07044687 | RECRUITING | Acute Myeloid Leukemia |
AbbVie |
2025-07-24 | PHASE4 |
| NCT06497062 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
Shanghai Jiao Tong University School of Medicine |
2024-10-30 | PHASE2 |
| NCT06523556 | RECRUITING | Atypical Chronic Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Myeloproliferative Neoplasm |
Uma Borate |
2024-08-02 | PHASE1; PHASE2 |
| NCT06686108 | RECRUITING | T-cell Acute Lymphoblastic Leukemia; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; Relapse |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2024-10-30 | PHASE2 |
| NCT06504459 | RECRUITING | Acute Monocytic Leukemia; Acute Myeloid Leukemia |
OHSU Knight Cancer Institute |
2025-01-03 | PHASE2 |
| NCT07632170 | NOT_YET_RECRUITING | Myeloid Tumors |
Bing Han |
2026-11-01 | |
| NCT06511882 | RECRUITING | Acute Myeloid Leukemia |
H. Lee Moffitt Cancer Center and Research Institute |
2024-11-07 | PHASE2 |
| NCT07486726 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML); Relapse Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia (AML) |
Shanghai Jiao Tong University School of Medicine |
2026-03-15 | PHASE1; PHASE2 |
| NCT05401097 | RECRUITING | Acute Myeloid Leukemia |
Alice Mims |
2022-09-13 | PHASE2 |
| NCT03683433 | RECRUITING | Acute Bilineal Leukemia; Acute Biphenotypic Leukemia; Chronic Myelomonocytic Leukemia; IDH2 Gene Mutation; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2018-09-18 | PHASE2 |
| NCT03326310 | RECRUITING | Chronic Myeloid Leukemia; Myelofibroses |
University of Chicago |
2018-09-04 | PHASE1 |
| NCT07743112 | RECRUITING | Acute Myeloid Leukemia |
Maxinovel Pty., Ltd. |
2025-09-05 | PHASE2 |
| NCT07761533 | RECRUITING | Acute Myeloid Leukemia (AML); MDS (Myelodysplastic Syndrome) |
Chaser Therapeutics, Inc. |
2025-09-08 | PHASE1; PHASE2 |
| NCT07132684 | RECRUITING | AML, Adult |
Institute of Hematology & Blood Diseases Hospital, China |
2025-08-31 | PHASE3 |
| NCT06616636 | RECRUITING | Myelodysplastic Syndrome; Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2025-01-30 | PHASE1 |
| NCT04227847 | RECRUITING | Myelodysplastic Syndrome; Acute Myeloid Leukemia |
Seagen, a wholly owned subsidiary of Pfizer |
2020-08-07 | PHASE1 |
| NCT05772273 | RECRUITING | Acute Myeloid Leukemia |
The First Affiliated Hospital of Soochow University |
2023-03-15 | |
| NCT06466798 | WITHDRAWN | Recurrent Ependymoma; Recurrent Medulloblastoma; CNS Malignancies |
Jeffrey Treiber |
2024-07-15 | PHASE1 |
| NCT04401748 | ACTIVE_NOT_RECRUITING | Myelodysplastic Syndrome (MDS) |
AbbVie |
2020-09-10 | PHASE3 |
| NCT06090786 | NOT_YET_RECRUITING | AML, Adult; Minimal Residual Disease |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2024-07 | |
| NCT06159491 | RECRUITING | Chronic Myelomonocytic Leukemia |
Douglas Tremblay |
2024-09-18 | PHASE1; PHASE2 |
| NCT07094464 | ACTIVE_NOT_RECRUITING | TP53-mutated MDS and AML; Allogeneic Hematopoietic Stem Cell Transplantation |
Daihong Liu |
2025-06-01 | PHASE1 |
| NCT06656494 | RECRUITING | Acute Myelogenous Leukemia; Myelodysplastic Syndromes (MDS) |
Beijing InnoCare Pharma Tech Co., Ltd. |
2024-12-18 | PHASE1 |
| NCT07548710 | RECRUITING | Acute Myeloid Leukemia |
Ruijin Hospital |
2026-05-01 | PHASE2 |
| NCT04803201 | RECRUITING | Angioimmunoblastic T-cell Lymphoma; Enteropathy-Associated T-Cell Lymphoma; Follicular T-Cell Lymphoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma; Nodal Peripheral T-Cell Lymphoma With TFH Phenotype; Peripheral T-Cell Lymphoma, Not Otherwise Specified |
Alliance for Clinical Trials in Oncology |
2021-10-08 | PHASE2 |
| NCT04150887 | ACTIVE_NOT_RECRUITING | Leukemia, Myeloid, Acute |
OncoVerity, Inc. |
2019-12-23 | PHASE1 |
| NCT04891068 | RECRUITING | Breast Cancer Invasive; Early-stage Breast Cancer; High Risk Breast Carcinoma |
University of Illinois at Chicago |
2022-01-10 | PHASE2 |
| NCT05162976 | ACTIVE_NOT_RECRUITING | Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma |
City of Hope Medical Center |
2022-01-03 | PHASE1 |
| NCT06498973 | RECRUITING | Acute Myeloid Leukemia; Myelodysplastic Syndrome |
City of Hope Medical Center |
2025-01-28 | PHASE1 |
| NCT05554406 | RECRUITING | Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy; Acute Myeloid Leukemia, Myelodysplasia-Related |
National Cancer Institute (NCI) |
2024-09-25 | PHASE2 |
| NCT07388563 | SUSPENDED | Lymphoma, T Cell, Peripheral; T-cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Monomorphic Epitheliotropic Intestinal T-cell Lymphoma; Adult T-cell Leukemia/Lymphoma |
National Cancer Institute (NCI) |
2026-03-26 | PHASE1 |
| NCT04068597 | RECRUITING | Haematological Malignancy; Acute Myeloid Leukemia; Non Hodgkin Lymphoma; Multiple Myeloma; Higher-risk Myelodysplastic Syndrome; Peripheral T Cell Lymphoma |
CellCentric Ltd. |
2019-08-09 | PHASE1; PHASE2 |
| NCT06357182 | RECRUITING | Acute Myeloid Leukemia; Myelodysplastic Syndrome/Acute Myeloid Leukemia |
OHSU Knight Cancer Institute |
2024-08-22 | PHASE1 |
| NCT04799275 | ACTIVE_NOT_RECRUITING | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation; Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Grade 3b Follicular Lymphoma; HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Intravascular Large B-Cell Lymphoma; Lymphoplasmacytic Lymphoma; Nodular Lymphocyte Predominant B-Cell Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; T-Cell/Histiocyte-Rich Large B-Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma |
National Cancer Institute (NCI) |
2021-05-20 | PHASE2; PHASE3 |
| NCT06372717 | RECRUITING | Acute Myeloid Leukemia Refractory; Myelodysplastic Syndrome Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts; Acute Myeloid Leukemia, in Relapse; Acute Myeloid Leukemia (AML) |
Apollo Therapeutics Ltd |
2024-06-04 | PHASE1 |
| NCT06896110 | ENROLLING_BY_INVITATION | Glioblastoma (GBM); Diffuse Midline Glioma (DMG); Astrocytoma, IDH-Mutant, Grade 4; Diffuse Hemispheric Glioma, H3 G34-Mutant; Gliosarcoma of Brain |
Andrew P. Groves |
2025-06-05 | PHASE1 |
| NCT05428969 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes; Relapsed/Refractory AML |
Faron Pharmaceuticals Ltd |
2022-06-02 | PHASE1; PHASE2 |
| NCT05183035 | RECRUITING | Acute Myeloid Leukemia |
PedAL BCU, LLC |
2022-10-01 | PHASE3 |
| NCT04086264 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
AbbVie |
2019-11-06 | PHASE1; PHASE2 |
| NCT03862157 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Chronic Eosinophilic Leukemia, Not Otherwise Specified; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Essential Thrombocythemia; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Myeloid Neoplasm; Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Unclassifiable; Overt Primary Myelofibrosis; Polycythemia Vera; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Prefibrotic/Early Primary Myelofibrosis |
M.D. Anderson Cancer Center |
2019-02-27 | PHASE1; PHASE2 |
| NCT06370000 | RECRUITING | Acute Myeloid Leukemia |
Virginia Commonwealth University |
2024-11-07 | PHASE4 |
| NCT06763341 | RECRUITING | Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
City of Hope Medical Center |
2025-07-30 | PHASE1 |
| NCT06754540 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML); Relapse |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2025-01-16 | PHASE2 |
| NCT04801797 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
Massachusetts General Hospital |
2021-05-20 | PHASE2 |
| NCT06384261 | ACTIVE_NOT_RECRUITING | Leukemia, Myeloid, Acute |
OncoVerity, Inc. |
2024-07-22 | PHASE2 |
| NCT06345365 | RECRUITING | Acute Myeloid Leukaemia |
Zhongnan Hospital |
2024-01-18 | PHASE3 |
| NCT05603884 | RECRUITING | Leukemia, Myeloid, Acute; AML Stage, Adult |
The First Affiliated Hospital of Xiamen University |
2022-12-01 | PHASE2 |
| NCT05355051 | RECRUITING | Hodgkin's Lymphoma |
M.D. Anderson Cancer Center |
2022-10-05 | PHASE2 |
| NCT07517510 | ENROLLING_BY_INVITATION | Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL) |
Guangdong Second Provincial General Hospital |
2026-04-01 | PHASE2 |
| NCT04128501 | ACTIVE_NOT_RECRUITING | Acute Bilineal Leukemia; Acute Biphenotypic Leukemia; Acute Myeloid Leukemia; Mixed Phenotype Acute Leukemia; T Acute Lymphoblastic Leukemia; Therapy-Related Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2020-05-05 | PHASE2 |
| NCT04588922 | RECRUITING | Hematologic Malignancies |
Sellas Life Sciences Group |
2021-05-10 | PHASE1; PHASE2 |
| NCT05958719 | RECRUITING | Peripheral T Cell Lymphoma; Epigenetic Repression |
Institute of Hematology & Blood Diseases Hospital, China |
2023-03-02 | PHASE2 |
| NCT06451861 | RECRUITING | Acute Myeloid Leukemia |
Guangdong Provincial People's Hospital |
2024-08-21 | PHASE2 |
| NCT06757855 | RECRUITING | CML,Blast Phase |
Institute of Hematology & Blood Diseases Hospital, China |
2025-01-26 | PHASE1; PHASE2 |
| NCT05376111 | RECRUITING | T-cell Acute Lymphoblastic Leukemia; Recruiting |
The First Affiliated Hospital of Soochow University |
2022-04-01 | PHASE2 |
| NCT06379360 | RECRUITING | Acute Myeloid Leukemia |
The First Affiliated Hospital of Soochow University |
2020-11-01 | PHASE2 |
| NCT06858618 | ACTIVE_NOT_RECRUITING | Safety; Antitumor Activity; PK Profile |
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
2023-08-16 | PHASE2 |
| NCT06190067 | RECRUITING | Relapsed Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma |
Navy General Hospital, Beijing |
2023-10-30 | PHASE2 |
| NCT06783790 | RECRUITING | AML (Acute Myelogenous Leukemia) |
Institute of Hematology & Blood Diseases Hospital, China |
2025-01-20 | PHASE2 |
| NCT07000617 | RECRUITING | NK/T Cell Lymphoma |
Peking University Cancer Hospital & Institute |
2025-03-21 | PHASE2 |
| NCT07303660 | RECRUITING | Acute Myeloid Leukemia |
Lomond Therapeutics Holdings, Inc. |
2025-11-14 | PHASE1 |
| NCT05955261 | SUSPENDED | Acute Myeloid Leukemia |
St. Jude Children's Research Hospital |
2023-07-25 | PHASE2 |
| NCT06066905 | RECRUITING | AML, Adult; Minimal Residual Disease |
Guangdong Provincial People's Hospital |
2023-10-26 | |
| NCT06377085 | ENROLLING_BY_INVITATION | Cerebral Palsy; Contracture |
Shirley Ryan AbilityLab |
2025-07 | PHASE1 |
| NCT05788679 | RECRUITING | Myelodysplastic Syndromes; Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts; Mixed Myelodysplastic/Myeloproliferative Disease |
Karolinska University Hospital |
2022-11-22 | PHASE2 |
| NCT05226455 | ACTIVE_NOT_RECRUITING | MDS; AML |
Groupe Francophone des Myelodysplasies |
2022-11-23 | PHASE1; PHASE2 |
| NCT04187703 | RECRUITING | Myelodysplastic Syndromes; MDS/MPN Crossover Syndromes |
Benjamin Tomlinson |
2020-11-16 | EARLY_PHASE1 |
| NCT06741722 | RECRUITING | AML; Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
Beijing 302 Hospital |
2024-10-31 | PHASE2 |
| NCT07490288 | RECRUITING | AML |
Institute of Hematology & Blood Diseases Hospital, China |
2026-05-08 | |
| NCT05453903 | ACTIVE_NOT_RECRUITING | Leukemia, Myeloid, Acute |
Janssen Research & Development, LLC |
2022-10-04 | PHASE1 |
| NCT07163793 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia in Remission |
Northwell Health |
2024-10-07 | PHASE2 |
| NCT06022003 | RECRUITING | AML, Adult; Refractory AML; Relapsed Adult AML; FLT3-TKD Mutation; FLT3-ITD |
French Innovative Leukemia Organisation |
2024-01-13 | PHASE2 |
| NCT05566054 | RECRUITING | Acute Monocytic Leukemia; Newly Diagnosed |
The First Affiliated Hospital of Soochow University |
2022-03-01 | PHASE2 |
| NCT05554419 | NOT_YET_RECRUITING | Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy; Secondary Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2026-07-01 | PHASE2 |
| NCT07081607 | NOT_YET_RECRUITING | Peripheral T-Cell Lymphoma, Not Classified |
Ruijin Hospital |
2025-07-15 | PHASE2 |
| NCT05675813 | RECRUITING | Peripheral T Cell Lymphoma |
Ruijin Hospital |
2023-02-13 | PHASE1; PHASE2 |
| NCT06055621 | RECRUITING | Acute Myeloid Leukemia |
Institut Paoli-Calmettes |
2024-05-22 | PHASE2 |
| NCT06483906 | RECRUITING | Acute Myeloid Leukemia |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2024-07-02 | PHASE2 |
| NCT06810791 | RECRUITING | Newly Diagnosed Acute Myeloid Leukemia With High Risk |
Nanfang Hospital, Southern Medical University |
2025-01-01 | PHASE3 |
| NCT06158100 | TERMINATED | Acute Myeloid Leukemia |
Antonio M Jimenez Jimenez |
2024-12-04 | PHASE1 |
| NCT07028086 | RECRUITING | Acute Myeloid Leukemia; Myeloid Sarcoma |
Ruijin Hospital |
2025-06-20 | PHASE2 |
| NCT06394011 | RECRUITING | Intermediate Risk Acute Myeloid Leukemia; High Risk Acute Myeloid Leukemia |
The First Affiliated Hospital of Soochow University |
2024-02-15 | PHASE2 |
| NCT05673057 | ACTIVE_NOT_RECRUITING | Leukemia; Myeloid; Acute; Newly Diagnosed |
Molecular Partners AG |
2022-12-29 | PHASE1; PHASE2 |
| NCT04550442 | TERMINATED | Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome; Therapy-Related Myelodysplastic Syndrome |
M.D. Anderson Cancer Center |
2020-09-04 | PHASE1; PHASE2 |
| NCT03613532 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myelomonocytic Leukemia (CMML); MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable); Hematopoietic Stem Cell Transplant |
Jacqueline Garcia, MD |
2018-10-24 | PHASE1 |
| NCT05768711 | ACTIVE_NOT_RECRUITING | Chronic Myeloid Leukemia |
Groupe Francophone des Myelodysplasies |
2023-10-04 | PHASE2 |
| NCT06572982 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
Hikma Pharmaceuticals LLC |
2025-04-29 | |
| NCT07007949 | RECRUITING | Acute Myeloid Leukemia; IDH1 Gene Mutation; Ivosidenib |
The First Affiliated Hospital of Soochow University |
2025-06-01 | PHASE2 |
| NCT04173533 | COMPLETED | Acute Myeloid Leukemia; Myelodysplasia |
University of Birmingham |
2019-06-14 | PHASE3 |
| NCT02942290 | COMPLETED | Myelodysplastic Syndromes (MDS) |
AbbVie |
2017-01-12 | PHASE1 |
| NCT06387420 | NOT_YET_RECRUITING | ACUTE MYELOID LEUKEMIA; AML |
Akeso |
2024-04-29 | PHASE1; PHASE2 |
| NCT07651475 | ACTIVE_NOT_RECRUITING | R/R AML |
Liping Dou |
2026-03-31 | PHASE2 |
| NCT04742101 | COMPLETED | Acute Myeloid Leukemia |
Institut de Recherches Internationales Servier |
2021-03-10 | PHASE1; PHASE2 |
| NCT02816021 | COMPLETED | Melanoma and Other Malignant Neoplasms of Skin; Metastatic Melanoma |
M.D. Anderson Cancer Center |
2017-02-14 | PHASE2 |
| NCT04184505 | RECRUITING | High-risk MDS |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2020-11-27 | PHASE3 |
| NCT04061239 | RECRUITING | MDS; AML |
GWT-TUD GmbH |
2019-08-19 | PHASE2 |
| NCT05144243 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia (AML) |
AbbVie |
2022-01-06 | PHASE4 |
| NCT05141682 | ACTIVE_NOT_RECRUITING | T-Cell Large Granular Lymphocyte Leukemia |
Jonathan Brammer |
2022-06-29 | PHASE1; PHASE2 |
| NCT06279338 | UNKNOWN | Myelodysplastic Syndromes |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2024-03-01 | |
| NCT06927232 | NOT_YET_RECRUITING | Higher-risk Myelodysplastic Syndrome |
Peking Union Medical College Hospital |
2025-04 | PHASE3 |
| NCT05305859 | RECRUITING | Leukemia, Myeloid, Acute; Relapsed Adult AML; Refractory Leukemia |
The First Affiliated Hospital of Xiamen University |
2022-01-12 | PHASE2 |
| NCT05379166 | ACTIVE_NOT_RECRUITING | Secondary Myelodysplastic Syndrome; Therapy-Related Myelodysplastic Syndrome |
Uma Borate |
2022-06-23 | PHASE2 |
| NCT01787487 | COMPLETED | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Myelofibrosis Transformation in Essential Thrombocythemia; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Primary Myelofibrosis |
M.D. Anderson Cancer Center |
2013-03-13 | PHASE2 |
| NCT04973618 | WITHDRAWN | AML |
Aptevo Therapeutics |
2025-01 | PHASE1 |
| NCT06196203 | RECRUITING | Higher-risk Myelodysplastic Syndromes |
Akeso |
2024-02-07 | PHASE2 |
| NCT04275518 | RECRUITING | Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS) |
Ascentage Pharma Group Inc. |
2020-07-06 | PHASE1 |
| NCT06737523 | RECRUITING | Acute Myeloid Leukemia; Relapse; Refractory AML |
The First Affiliated Hospital of Xiamen University |
2025-03-15 | PHASE1 |
| NCT05325099 | RECRUITING | Acute Kidney Disease |
National Taiwan University Hospital |
2024-04-18 | PHASE1; PHASE2 |
| NCT05829226 | COMPLETED | AML, Adult Recurrent; MDS |
PureTech |
2022-12-12 | PHASE1 |
| NCT06746519 | RECRUITING | Acute Myeloid Leukemia |
Chen Suning |
2024-12-25 | PHASE1; PHASE2 |
| NCT04139434 | COMPLETED | AML/MDS; CMML; Relapse; Refractory Acute Lymphoblastic Leukemia; Relapse Leukemia; Relapsed Adult AML |
Newave Pharmaceutical Inc |
2020-07-06 | PHASE1 |
| NCT05782127 | ACTIVE_NOT_RECRUITING | Untreated Myelodysplastic Syndrome |
Groupe Francophone des Myelodysplasies |
2023-12-06 | PHASE1; PHASE2 |
| NCT04229979 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
Sellas Life Sciences Group |
2021-02-08 | PHASE3 |
| NCT06550713 | RECRUITING | Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS) |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2019-10-22 | PHASE1 |
| NCT05833438 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia (AML) |
University of Leipzig |
2023-05-17 | PHASE2 |
| NCT05476770 | RECRUITING | Hematologic Malignancy; AML; ALL; BPDCN; MDS; Lymphoblastic Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Hodgkin Lymphoma; Mixed Phenotype Acute Leukemia; Acute Undifferentiated Leukemia |
Therapeutic Advances in Childhood Leukemia Consortium |
2022-11-11 | PHASE1 |
| NCT03564873 | ACTIVE_NOT_RECRUITING | High Grade Myelodysplastic Syndromes |
University of Colorado, Denver |
2018-09-17 | PHASE1; PHASE2 |
| NCT07011186 | RECRUITING | Myeloid Malignancy |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2024-04-17 | PHASE1; PHASE2 |
| NCT06664970 | ENROLLING_BY_INVITATION | MDS |
Peking Union Medical College Hospital |
2024-11-06 | PHASE2 |
| NCT03164057 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Myelodysplastic Syndromes |
St. Jude Children's Research Hospital |
2017-06-15 | PHASE2 |
| NCT04980885 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
Akeso |
2021-08-13 | PHASE1; PHASE2 |
| NCT03895671 | COMPLETED | CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE; CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS |
Versailles Hospital |
2019-06-19 | PHASE2 |
| NCT06326697 | COMPLETED | Acute Myeloid Leukaemia |
Hikma Pharmaceuticals LLC |
2024-05-02 | PHASE1 |
| NCT06508489 | TERMINATED | Acute Myeloid Leukemia |
Sanofi |
2024-08-13 | PHASE1; PHASE2 |
| NCT06586099 | WITHDRAWN | Refractory AML; Relapsed Adult AML |
Institute of Hematology & Blood Diseases Hospital, China |
2024-10-05 | PHASE1; PHASE2 |
| NCT04905810 | RECRUITING | Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia |
Brian Jonas |
2022-02-09 | PHASE2 |
| NCT06008405 | UNKNOWN | Acute Myeloid Leukemia; Myelodysplastic Syndromes |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2023-09 | PHASE1 |
| NCT04937166 | TERMINATED | Acute Myeloid Leukemia; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia |
Kahr Medical |
2022-01-13 | PHASE1 |
| NCT02494258 | COMPLETED | Hematologic Neoplasm; Neoplasms; Hematologic Malignancies |
Celgene |
2015-10-22 | PHASE2 |
| NCT06449482 | TERMINATED | Acute Myeloid Leukemia, Adult |
Institute of Hematology & Blood Diseases Hospital, China |
2023-05-05 | PHASE1; PHASE2 |
| NCT05736965 | RECRUITING | AML, Adult |
Shanghai Tong Ren Hospital |
2023-02-20 | PHASE2 |
| NCT04435691 | TERMINATED | Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2020-07-28 | PHASE1; PHASE2 |
| NCT05736978 | RECRUITING | AML; MRD |
Shanghai Tong Ren Hospital |
2023-03-31 | PHASE2 |
| NCT06256627 | RECRUITING | Acute Myeloid Leukemia; Maintenance Treatment; Minor Residue Disease; Interferon-α-1b; Interleukin-2; Thalidomide; Venentoclax; Azacitidine |
Henan Cancer Hospital |
2023-07-11 | |
| NCT04913922 | UNKNOWN | Acute Myeloid Leukemia |
Ludwig-Maximilians - University of Munich |
2021-05-05 | PHASE2 |
| NCT06150040 | TERMINATED | Acute Myeloid Leukemia Refractory |
Centre Leon Berard |
2024-09-11 | PHASE1; PHASE2 |
| NCT05197426 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia |
Bristol-Myers Squibb |
2022-01-17 | PHASE2 |
| NCT04553692 | TERMINATED | Solid Tumor; Colorectal Cancer; Non Hodgkin Lymphoma; Sarcoma; Chondrosarcoma; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia; Acute Myeloid Leukemia |
IGM Biosciences, Inc. |
2020-09-23 | PHASE1 |
| NCT04417517 | TERMINATED | Higher Risk Myelodysplastic Syndromes |
ALX Oncology Inc. |
2020-10-02 | PHASE1 |
| NCT05609942 | TERMINATED | Advanced Systemic Mastocytosis |
Blueprint Medicines Corporation |
2023-09-25 | PHASE1 |
| NCT05817955 | RECRUITING | MDS/MPN |
The First Affiliated Hospital with Nanjing Medical University |
2022-11-01 | PHASE2 |
| NCT04867928 | UNKNOWN | Acute Myeloid Leukemia; Acute Myeloid Leukemia, in Relapse; NPM1 Mutation |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2022-03-01 | PHASE2 |
| NCT05149378 | COMPLETED | Acute T-Lymphocytic Leukemia |
The First Affiliated Hospital of Soochow University |
2021-11-01 | PHASE2 |
| NCT05662956 | COMPLETED | Acute Myeloid Leukemia |
Hematology department of the 920th hospital |
2022-12-01 | PHASE2 |
| NCT04052659 | UNKNOWN | Peripheral T-cell Lymphoma |
Peking University |
2021-04-15 | PHASE2 |
| NCT05883956 | ACTIVE_NOT_RECRUITING | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Patient Preference |
Otsuka Australia Pharmaceutical Pty Ltd |
2023-12-20 | PHASE3 |
| NCT06224842 | UNKNOWN | Angioimmunoblastic T-cell Lymphoma |
Huijing Wu |
2023-12-12 | PHASE1; PHASE2 |
| NCT04687761 | COMPLETED | Leukemia, Myeloid, Acute; De Novo; Age More 60yr |
PETHEMA Foundation |
2020-11-04 | PHASE1; PHASE2 |
| NCT06073730 | UNKNOWN | Elderly AML Patients; Unfit, New-diagnosis AML; Acute Myeloid Leukemia; Venetoclax; Decitabine |
The Second Affiliated Hospital of Kunming Medical University |
2023-11-01 | PHASE3 |
| NCT04150029 | TERMINATED | Acute Myeloid Leukemia |
Novartis Pharmaceuticals |
2020-09-01 | PHASE2 |
| NCT04266301 | TERMINATED | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic |
Novartis Pharmaceuticals |
2020-06-08 | PHASE3 |
| NCT06030089 | COMPLETED | Acute Myeloid Leukemia |
Centre Hospitalier Universitaire de Nice |
2024-02-26 | |
| NCT05654194 | COMPLETED | Acute Myeloid Leukemia |
The First Affiliated Hospital of Soochow University |
2022-10-31 | PHASE3 |
| NCT06078306 | UNKNOWN | B Acute Lymphoblastic Leukemia; Ph-Negative ALL; High Risk Acute Lymphoblastic Leukemia |
The First Affiliated Hospital of Soochow University |
2024-04-20 | PHASE2 |
| NCT04905407 | TERMINATED | Acute Myeloid Leukemia |
Syros Pharmaceuticals |
2021-08-26 | PHASE2 |
| NCT05168202 | TERMINATED | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes |
Bristol-Myers Squibb |
2022-01-19 | PHASE1 |
| NCT02269280 | COMPLETED | Leukemia |
M.D. Anderson Cancer Center |
2014-10-13 | PHASE2 |
| NCT03530683 | TERMINATED | Lymphoma; Multiple Myeloma; Acute Myeloid Leukemia; Diffuse Large B-Cell Lymphoma |
Pfizer |
2018-05-14 | PHASE1 |
| NCT03594149 | COMPLETED | Myelodysplastic Syndromes; Acute Myeloid Leukemia |
Centre Henri Becquerel |
2018-07-18 | PHASE3 |
| NCT04447027 | COMPLETED | Cutaneous T-Cell Lymphoma; Mature T-cell Malignancies; Peripheral T-Cell Lymphoma; Relapsed/ Refractory T-cell Malignancies |
National Cancer Institute (NCI) |
2020-12-17 | PHASE1 |
| NCT05797948 | UNKNOWN | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
The First Affiliated Hospital of Soochow University |
2022-07-01 | |
| NCT05805072 | UNKNOWN | Relapsed/Refractory AML |
The First Affiliated Hospital of Soochow University |
2023-05-01 | |
| NCT05126004 | UNKNOWN | Thrombocytopenia, Isolated; Stem Cell Transplant Complications |
The First Affiliated Hospital of Soochow University |
2021-12-01 | PHASE2 |
| NCT05448599 | UNKNOWN | Acute Myeloid Leukemia; Myelodysplastic Syndrome |
Mabwell (Shanghai) Bioscience Co., Ltd. |
2022-07-08 | PHASE1; PHASE2 |
| NCT03765541 | TERMINATED | Relapsed or Refractory Acute Myeloid Leukemia |
University Hospital, Toulouse |
2020-01-13 | PHASE3 |
| NCT05433532 | COMPLETED | Philadelphia Chromosome; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Mixed Phenotype Acute Leukemia |
The First Affiliated Hospital of Soochow University |
2022-05-01 | PHASE2 |
| NCT06372717 | Not yet recruiting | Acute Myeloid Leukemia Refractory|Myelodysplastic Syndrome Acute Myeloid Leukemia|Myelodysplastic Syndrome With Excess Blasts|Acute Myeloid Leukemia in Relapse |
Apollo Therapeutics Ltd |
2024-04 | Phase 1|Phase 2 |
| NCT06263387 | Not yet recruiting | AML Adult |
French Innovative Leukemia Organisation|Acute Leukemia French Association |
2024-04-29 | -- |
| NCT05559008 | UNKNOWN | Peripheral T Cell Lymphoma |
Ruijin Hospital |
2022-09-30 | PHASE1; PHASE2 |
| NCT04778397 | TERMINATED | Acute Myeloid Leukemia |
Gilead Sciences |
2021-07-01 | PHASE3 |
| NCT03226418 | COMPLETED | Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia |
University of Nebraska |
2017-07-07 | PHASE2 |
| NCT04778410 | TERMINATED | Myeloid Malignancies |
Gilead Sciences |
2021-06-28 | PHASE2 |
| NCT05140811 | UNKNOWN | Acute Myeloid Leukemia; Myelodysplastic Syndromes |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. |
2022-01-05 | PHASE1; PHASE2 |
| NCT06109064 | UNKNOWN | Myelodysplastic Syndromes |
Anhui Provincial Hospital |
2023-10-27 | PHASE2 |
| NCT05807347 | UNKNOWN | Refractory/Relapse Acute Myeloid Leukemia |
Hematology department of the 920th hospital |
2023-02-01 | PHASE2 |
| NCT06105658 | UNKNOWN | Acute Myelocytic Leukemia |
Anhui Provincial Hospital |
2023-10 | PHASE2 |
| NCT06159491 | Not yet recruiting | Chronic Myelomonocytic Leukemia |
Douglas Tremblay|Sobi Inc.|Icahn School of Medicine at Mount Sinai |
2024-01-02 | Phase 1|Phase 2 |
| NCT06022003 | Recruiting | AML Adult|Refractory AML|Relapsed Adult AML|FLT3-TKD Mutation|FLT3-ITD |
French Innovative Leukemia Organisation|Acute Leukemia French Association |
2024-01-13 | Phase 2 |
| NCT06014489 | Recruiting | AML Adult |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2024-01-17 | Phase 2 |
| NCT05823701 | UNKNOWN | Diffuse Large B-Cell Lymphoma |
The First Affiliated Hospital of Soochow University |
2022-09-30 | PHASE2 |
| NCT04485065 | SUSPENDED | Myelodysplastic Syndromes |
Innovent Biologics (Suzhou) Co. Ltd. |
2020-09-30 | PHASE1 |
| NCT02719574 | COMPLETED | Acute Myeloid Leukemia; Acute Myelogenous Leukemia; Myelodysplastic Syndrome |
Forma Therapeutics, Inc. |
2016-04-30 | PHASE1; PHASE2 |
| NCT05209152 | TERMINATED | Higher Risk Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia |
Amgen |
2022-11-14 | PHASE1 |
| NCT04202003 | COMPLETED | Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes(MDS) |
TJ Biopharma Co., Ltd. |
2020-03-25 | PHASE1; PHASE2 |
| NCT04578600 | COMPLETED | Indolent B-Cell Non-Hodgkin Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma; Recurrent Follicular Lymphoma; Recurrent Hairy Cell Leukemia; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Mucosa-Associated Lymphoid Tissue Lymphoma; Refractory Follicular Lymphoma; Refractory Hairy Cell Leukemia; Refractory Lymphoplasmacytic Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Small Lymphocytic Lymphoma |
Joseph Tuscano |
2020-10-23 | PHASE1 |
| NCT03513484 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A; Fibroblast Growth Factor Basic Form Measurement; FLT3 Internal Tandem Duplication; Recurrent Adult Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
Northwestern University |
2018-11-14 | PHASE1 |
| NCT03932318 | WITHDRAWN | Acute Myeloid Leukemia; Relapsed Adult AML |
Actinium Pharmaceuticals |
2023-03 | PHASE1; PHASE2 |
| NCT05772728 | UNKNOWN | T Cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2023-04 | |
| NCT04878432 | TERMINATED | Myelodysplastic Syndrome (MDS) |
Novartis Pharmaceuticals |
2022-03-17 | PHASE2 |
| NCT04336982 | TERMINATED | Leukemia, Myeloid, Acute |
Celgene |
2020-08-05 | PHASE1 |
| NCT06085638 | WITHDRAWN | Chronic Myelomonocytic Leukemia |
M.D. Anderson Cancer Center |
2023-09-14 | PHASE1; PHASE2 |
| NCT02397720 | COMPLETED | Acute Bilineal Leukemia; Acute Biphenotypic Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2015-04-07 | PHASE2 |
| NCT04958486 | COMPLETED | Fossa Ependymoma |
The University of Texas Health Science Center, Houston |
2021-07-08 | EARLY_PHASE1 |
| NCT04313881 | TERMINATED | Myelodysplastic Syndromes |
Gilead Sciences |
2020-09-09 | PHASE3 |
| NCT03066648 | COMPLETED | Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Preleukemia; Bone Marrow Diseases; Hematologic Diseases; Chronic Myelomonocytic Leukemia |
Novartis Pharmaceuticals |
2017-07-06 | PHASE1 |
| NCT03248479 | TERMINATED | Hematological Malignancies |
Gilead Sciences |
2017-09-08 | PHASE1 |
| NCT05042531 | UNKNOWN | Acute Myeloid Leukemia |
LanZhou University |
2021-11-13 | |
| NCT04629443 | COMPLETED | Acute Myeloid Leukaemia |
Institut de Recherches Internationales Servier |
2021-02-17 | PHASE1; PHASE2 |
| NCT05495100 | UNKNOWN | Peripheral T Cell Lymphoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2022-08-11 | PHASE2 |
| NCT03092674 | COMPLETED | Acute Myeloid Leukemia; Myelodysplastic Syndrome; Myelodysplastic Syndrome/Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2018-02-02 | PHASE2; PHASE3 |
| NCT05262465 | UNKNOWN | Adult Acute Myeloid Leukemia |
guomei |
2020-07-01 | |
| NCT05266274 | UNKNOWN | Patients With Recurrent Acute Myelogenous Leukemia After Transplantation |
The First Affiliated Hospital of Soochow University |
2021-12-14 | |
| NCT04284787 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia Post Cytotoxic Therapy; Secondary Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2021-02-16 | PHASE2 |
| NCT03825367 | UNKNOWN | AML, Childhood |
Therapeutic Advances in Childhood Leukemia Consortium |
2019-11-29 | PHASE1; PHASE2 |
| NCT04812548 | TERMINATED | Myelodysplastic Syndrome (MDS) |
Novartis Pharmaceuticals |
2021-05-31 | PHASE2 |
| NCT03941496 | WITHDRAWN | Tuberculosis, Pulmonary |
Andrew Dinardo |
2022-10 | PHASE1; PHASE2 |
| NCT04407442 | TERMINATED | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
University of California, San Francisco |
2020-11-30 | PHASE2 |
| NCT02966782 | COMPLETED | Myelodysplastic Syndromes (MDS) |
AbbVie |
2017-03-07 | PHASE1 |
| NCT01928576 | COMPLETED | Non-Small Cell Lung Cancer; Epigenetic Therapy |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2013-11-06 | PHASE2 |
| NCT05471700 | COMPLETED | Leukemia, Myeloid, Acute |
Zhujiang Hospital |
2022-09-01 | |
| NCT03047993 | COMPLETED | Acute Myeloid Leukemia With Multilineage Dysplasia; Blasts 20-30 Percent of Bone Marrow Nucleated Cells; Blasts 20-30 Percent of Peripheral Blood White Cells; Chronic Myelomonocytic Leukemia; High Risk Myelodysplastic Syndrome; IPSS Risk Category Intermediate-2; Myelodysplastic Syndrome |
M.D. Anderson Cancer Center |
2017-11-15 | PHASE1; PHASE2 |
| NCT02752035 | COMPLETED | Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation |
Astellas Pharma Global Development, Inc. |
2016-08-01 | PHASE3 |
| NCT05361057 | TERMINATED | Acute Myeloid Leukemia; Measurable Disease |
Institute of Hematology & Blood Diseases Hospital, China |
2022-06-29 | PHASE2 |
| NCT03666559 | UNKNOWN | Recurrent IDH1/2 Mutated Glioma |
Assistance Publique - Hôpitaux de Paris |
2020-09-22 | PHASE2 |
| NCT04487106 | COMPLETED | Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome |
M.D. Anderson Cancer Center |
2020-07-21 | PHASE2 |
| NCT01892371 | COMPLETED | FLT3 Gene Mutation Negative; FLT3 Internal Tandem Duplication Positive; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome |
M.D. Anderson Cancer Center |
2013-11-12 | PHASE1; PHASE2 |
| NCT04712942 | COMPLETED | Acute Myeloid Leukemia in Remission; Myelodysplastic Syndromes; Minimal Residual Disease |
University of Leipzig |
2021-01-01 | PHASE2 |
| NCT02807558 | COMPLETED | Acute Myeloid Leukemia; Myelodysplastic Syndrome |
Syros Pharmaceuticals |
2016-09-20 | PHASE2 |
| NCT04505995 | UNKNOWN | JMML |
Air Force Military Medical University, China |
2020-01-01 | |
| NCT05457361 | UNKNOWN | Venetoclax Combined With Azacitidine Plus Homoharringtonine; Venetoclax Combined With Azacitidine |
Nanfang Hospital, Southern Medical University |
2022-03-01 | PHASE3 |
| NCT04842604 | COMPLETED | Acute Myeloid Leukemia; Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia |
Pfizer |
2021-05-17 | PHASE3 |
| NCT04639843 | WITHDRAWN | Adult T-cell Leukemia/Lymphoma; Extranodal NK-/T-cell Lymphoma, Nasal Type; Enteropathy-Associated T-Cell Lymphoma; Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma; Hepatosplenic T-cell Lymphoma |
National Cancer Institute (NCI) |
2022-11-03 | PHASE1 |
| NCT04266795 | COMPLETED | Acute Myeloid Leukemia (AML) |
Takeda |
2020-10-13 | PHASE2 |
| NCT04248595 | UNKNOWN | Acute Myeloid Leukemia |
Ge Zheng |
2019-12-01 | PHASE2 |
| NCT03206021 | COMPLETED | Recurrent Childhood CNS Tumor; Ependymoma, Recurrent Childhood; Childhood Solid Tumor |
The Hospital for Sick Children |
2017-08-01 | PHASE1 |
| NCT05282719 | UNKNOWN | Myelodysplastic/Myeloproliferative Neoplasms; Adult |
The First Affiliated Hospital of Soochow University |
2022-04 | PHASE2 |
| NCT02981615 | COMPLETED | Prevention |
Sheba Medical Center |
2017-08-01 | PHASE3 |
| NCT04480125 | UNKNOWN | Peripheral T-cell Lymphoma |
Ruijin Hospital |
2020-06-20 | PHASE2 |
| NCT03572387 | COMPLETED | Prostatic Neoplasms; Prostate Neoplasms; Prostate Cancer |
Icahn School of Medicine at Mount Sinai |
2018-08-20 | PHASE2 |
| NCT02203773 | TERMINATED | Acute Myelogenous Leukemia; Myelogenous Leukemia; Treatment Naive AML |
AbbVie |
2014-10-06 | PHASE1 |
| NCT04866056 | TERMINATED | Myelodysplastic Syndromes; Myeloproliferative Neoplasms; Myelofibrosis |
Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
2021-09-30 | PHASE1; PHASE2 |
| NCT04638309 | TERMINATED | MDS; Myelodysplastic Syndromes |
Aprea Therapeutics |
2021-09-20 | PHASE1 |
| NCT04264806 | WITHDRAWN | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic |
Janssen Research & Development, LLC |
2021-05-06 | PHASE2 |
| NCT02712905 | TERMINATED | Solid Tumors and Hematologic Malignancy |
Incyte Corporation |
2016-05-05 | PHASE1; PHASE2 |
| NCT03941964 | COMPLETED | Acute Myeloid Leukemia (AML); Cancer |
AbbVie |
2019-08-15 | PHASE3 |
| NCT04748848 | TERMINATED | Leukemia, Myeloid |
Celgene |
2021-10-14 | PHASE1 |
| NCT03390296 | COMPLETED | Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2017-12-27 | PHASE1; PHASE2 |
| NCT02782468 | COMPLETED | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes |
Millennium Pharmaceuticals, Inc. |
2016-05-16 | PHASE1 |
| NCT04214860 | COMPLETED | Myeloid Malignancy |
Aprea Therapeutics |
2019-12-13 | PHASE1 |
| NCT03614728 | TERMINATED | Neoplasms |
GlaxoSmithKline |
2018-10-16 | PHASE1; PHASE2 |
| NCT02124174 | UNKNOWN | Acute Myelogenous Leukemia AML; Myelodysplastic Syndrome MDS |
Patrick Stiff |
2012-01 | PHASE2 |
| NCT02993523 | ACTIVE_NOT_RECRUITING | Acute Myeloid Leukemia (AML) |
AbbVie |
2017-02-02 | PHASE3 |
| NCT03719989 | UNKNOWN | Diffuse Large B Cell Lymphoma; Relapsed Non Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma |
Seoul National University Hospital |
2018-12-01 | PHASE2 |
| NCT03094637 | UNKNOWN | High Risk Myelodysplastic Syndrome; IPSS Risk Category Intermediate-1; Myelodysplastic Syndrome |
M.D. Anderson Cancer Center |
2017-11-06 | PHASE2 |
| NCT04146038 | COMPLETED | Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia |
Rutgers, The State University of New Jersey |
2020-10-26 | PHASE2 |
| NCT04518345 | COMPLETED | Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia |
Uma Borate |
2020-11-05 | EARLY_PHASE1 |
| NCT03813147 | COMPLETED | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome |
National Cancer Institute (NCI) |
2019-05-17 | PHASE1 |
| NCT01305499 | UNKNOWN | Acute Myeloid Leukemia |
Hetty Carraway |
2011-07-01 | PHASE2 |
| NCT03113643 | RECRUITING | Acute Myeloid Leukemia; Myelodysplastic Syndrome; Blastic Plasmacytoid Dendritic Cell Neoplasm |
Dana-Farber Cancer Institute |
2017-06-26 | PHASE1 |
| NCT02829840 | WITHDRAWN | Leukemia; FLT3-Mutated Acute Myeloid Leukemia; FLT3-Mutated High-Risk Myelodysplastic Syndrome |
M.D. Anderson Cancer Center |
2016-09 | PHASE1; PHASE2 |
| NCT03931291 | COMPLETED | Acute Myeloid Leukemia or Myelodysplastic Syndromes |
Aprea Therapeutics |
2019-09-16 | PHASE2 |
| NCT03745352 | WITHDRAWN | Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2019-05-20 | PHASE2 |
| NCT03268954 | COMPLETED | Myelodysplastic Syndrome; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute |
Takeda |
2017-11-28 | PHASE3 |
| NCT03684811 | COMPLETED | Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme); Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 3a and 3b: Chondrosarcoma; Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma; Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations |
Forma Therapeutics, Inc. |
2018-11-01 | PHASE1; PHASE2 |
| NCT01845805 | COMPLETED | Pancreatic Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2014-01-10 | PHASE2 |
| NCT03814005 | COMPLETED | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute; Renal Insufficiency; Liver Disease; Neoplasms |
Takeda |
2019-07-10 | PHASE1 |
| NCT02038777 | COMPLETED | Acute Myeloid Leukemia |
Pfizer |
2014-03-25 | PHASE1 |
| NCT03397173 | COMPLETED | Myelodysplastic Syndromes; Myeloproliferative Neoplasm; Acute Myeloid Leukemia |
Case Comprehensive Cancer Center |
2018-03-16 | PHASE2 |
| NCT03701295 | COMPLETED | Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL; Leukemia Cutis; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2020-03-06 | PHASE1; PHASE2 |
| NCT03151304 | TERMINATED | Myelodysplastic Syndromes |
Helsinn Healthcare SA |
2017-06-01 | PHASE2 |
| NCT03745716 | COMPLETED | MDS |
Aprea Therapeutics |
2019-01-11 | PHASE3 |
| NCT03572530 | COMPLETED | Recurrent Ependymoma |
The University of Texas Health Science Center, Houston |
2019-02-08 | PHASE1 |
| NCT03194932 | COMPLETED | Acute Myeloid Leukemia |
St. Jude Children's Research Hospital |
2017-07-11 | PHASE1 |
| NCT02828358 | COMPLETED | Acute Leukemia of Ambiguous Lineage; B Acute Lymphoblastic Leukemia; Mixed Phenotype Acute Leukemia |
National Cancer Institute (NCI) |
2017-04-01 | PHASE2 |
| NCT04128020 | WITHDRAWN | Aml; AML, Adult |
Sherif Farag |
2019-10-10 | PHASE1 |
| NCT03493646 | COMPLETED | Myelodysplastic Syndromes; Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia |
Kirby Institute |
2018-05-18 | PHASE2 |
| NCT02319369 | TERMINATED | Acute Myelogenous Leukemia; Myelodysplastic Syndrome |
Daiichi Sankyo |
2014-11-25 | PHASE1 |
| NCT03151408 | TERMINATED | Acute Myeloid Leukemia |
Helsinn Healthcare SA |
2017-06-23 | PHASE3 |
| NCT02497404 | COMPLETED | Leukemia, Erythroblastic, Acute; Myelodysplastic Syndromes |
Weill Medical College of Cornell University |
2015-02-13 | PHASE2 |
| NCT03416179 | COMPLETED | Leukemia, Myeloid, Acute |
Pfizer |
2018-04-20 | PHASE3 |
| NCT01700673 | COMPLETED | Acute Myeloid Leukemia; Myelodysplastic Syndrome |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2013-06 | PHASE2 |
| NCT03588078 | UNKNOWN | Myelodysplastic Syndrome With Gene Mutation; Acute Myeloid Leukemia With Gene Mutations; Myeloproliferative Neoplasm; Chronic Myelomonocytic Leukemia |
Groupe Francophone des Myelodysplasies |
2018-09-15 | PHASE1; PHASE2 |
| NCT01404741 | COMPLETED | Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia |
Universitätsklinikum Hamburg-Eppendorf |
2011-07 | PHASE2 |
| NCT02472691 | COMPLETED | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic |
Heinrich-Heine University, Duesseldorf |
2015-05 | PHASE2 |
| NCT02942758 | TERMINATED | Acute Myeloid Leukemia |
University Hospital Regensburg |
2017-04-10 | PHASE2 |
| NCT02577406 | COMPLETED | Leukemia, Myeloid; Isocitrate Dehydrogenase |
Celgene |
2015-12-30 | PHASE3 |
| NCT02367456 | COMPLETED | Myelodysplastic Syndrome; Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia |
Pfizer |
2015-04-28 | PHASE1 |
| NCT02343536 | COMPLETED | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular |
Celgene |
2015-04-29 | PHASE1 |
| NCT01720225 | COMPLETED | Leukemia |
M.D. Anderson Cancer Center |
2012-11-06 | PHASE2 |
| NCT01998035 | TERMINATED | Lymphoid Malignancies; Lymphoma; Hodgkin Lymphoma; Non-hodgkin Lymphoma |
Columbia University |
2013-11 | PHASE1; PHASE2 |
| NCT02951156 | TERMINATED | Diffuse Large B-Cell Lymphoma |
Pfizer |
2016-12-16 | PHASE3 |
| NCT02017457 | COMPLETED | Acute Myelogenous Leukemia; Myelodysplastic Syndrome |
Carlos Graux, MD, PhD |
2013-12 | PHASE2 |
| NCT03338348 | COMPLETED | Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) |
University of Ulm |
2018-04-19 | PHASE2 |
| NCT03486353 | WITHDRAWN | Myelodysplastic Syndrome (MDS) |
Fujifilm Pharmaceuticals U.S.A., Inc. |
2019-10-01 | PHASE2 |
| NCT02953561 | TERMINATED | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2017-02-20 | PHASE1; PHASE2 |
| NCT03483948 | TERMINATED | Acute Myeloid Leukemia |
Hutchison Medipharma Limited |
2018-10-09 | PHASE1 |
| NCT02610777 | COMPLETED | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute |
Millennium Pharmaceuticals, Inc. |
2016-04-14 | PHASE2 |
| NCT01839240 | COMPLETED | Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia |
University of Chicago |
2012-06-06 | PHASE1 |
| NCT01460498 | COMPLETED | Leukemia |
M.D. Anderson Cancer Center |
2012-08-08 | PHASE1 |
| NCT03182894 | WITHDRAWN | Metastatic Colorectal Cancer |
James J Lee |
2018-09-30 | PHASE1; PHASE2 |
| NCT01636609 | TERMINATED | Acute Myeloid Leukemia; High Risk Myelodysplastic Syndrome |
M.D. Anderson Cancer Center |
2012-11-20 | PHASE1 |
| NCT02281084 | COMPLETED | Myelodysplastic Syndromes |
Celgene |
2015-07-06 | PHASE2 |
| NCT02508870 | COMPLETED | Myelodysplastic Syndromes |
Hoffmann-La Roche |
2015-09-30 | PHASE1 |
| NCT03612739 | WITHDRAWN | AML, Adult; Myelodysplastic Syndromes |
Celyad Oncology SA |
2018-12 | PHASE1 |
| NCT02117219 | COMPLETED | Myelodysplastic Syndrome |
MedImmune LLC |
2014-05-20 | PHASE1 |
| NCT00946647 | COMPLETED | Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia |
Novartis Pharmaceuticals |
2009-12-02 | PHASE1; PHASE2 |
| NCT03146871 | TERMINATED | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Recurrent Adult Acute Myeloid Leukemia |
University of Southern California |
2017-04-20 | PHASE2 |
| NCT02458235 | COMPLETED | Acute Myelogenous Leukemia; Acute Lymphoid Leukemia; Juvenile Myelomonocytic Leukemia; Myelodysplastic Syndrome |
University of California, San Francisco |
2015-06-02 | PHASE2 |
| NCT02543879 | COMPLETED | Acute Myeloid Leukemia; Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Non-Hodgkin Lymphoma |
Forma Therapeutics, Inc. |
2015-09 | PHASE1 |
| NCT03699384 | WITHDRAWN | Acute Myeloid Leukemia (AML); Minimal Residual Disease |
Memorial Sloan Kettering Cancer Center |
2018-10-03 | PHASE1; PHASE2 |
| NCT02959437 | TERMINATED | Solid Tumors; Advanced Malignancies; Metastatic Cancer |
Incyte Corporation |
2017-02-27 | PHASE1; PHASE2 |
| NCT02711137 | TERMINATED | Solid Tumors |
Incyte Corporation |
2016-05-18 | PHASE1; PHASE2 |
| NCT02599649 | TERMINATED | Leukemia |
M.D. Anderson Cancer Center |
2016-03-21 | PHASE2 |
| NCT01566695 | COMPLETED | Myelodysplastic Syndrome |
Celgene |
2013-04-26 | PHASE3 |
| NCT03259516 | TERMINATED | Myelodysplastic Syndromes |
St. Petersburg State Pavlov Medical University |
2017-05-25 | PHASE1; PHASE2 |
| NCT02940483 | COMPLETED | Brain Tumor Recurrent |
The University of Texas Health Science Center, Houston |
2017-02-01 | EARLY_PHASE1 |
| NCT02196857 | COMPLETED | Leukemia |
M.D. Anderson Cancer Center |
2015-02-06 | PHASE2 |
| NCT02811497 | COMPLETED | Microsatellite Stable Colorectal Carcinoma; Platinum Resistant Epithelial Ovarian Cancer Type II; Estrogen Receptor Positive and HER2 Negative Breast Cancer |
University Health Network, Toronto |
2016-09 | PHASE2 |
| NCT02995655 | COMPLETED | Myelodysplastic Syndromes; Acute Myeloid Leukemia; AML; MDS |
Washington University School of Medicine |
2017-04-07 | PHASE1 |
| NCT02343939 | TERMINATED | Acute Myeloid Leukemia |
Gilead Sciences |
2015-07-01 | PHASE1; PHASE2 |
| NCT01747499 | TERMINATED | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Washington University School of Medicine |
2013-04-15 | PHASE1; PHASE2 |
| NCT02677922 | ACTIVE_NOT_RECRUITING | Leukemia, Myeloid, Acute |
Celgene |
2016-06-03 | PHASE1; PHASE2 |
| NCT01462578 | COMPLETED | Acute Myelocytic Leukemia; Myelodysplastic Syndrome |
Technische Universität Dresden |
2011-09 | PHASE2 |
| NCT02399917 | TERMINATED | Acute Biphenotypic Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2015-04-20 | PHASE2 |
| NCT01342692 | UNKNOWN | MDS |
Assistance Publique - Hôpitaux de Paris |
2011-06 | PHASE2 |
| NCT02223052 | COMPLETED | Hematological Neoplasms; Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma; Lymphoma; Multiple Myeloma; Acute Myeloid Leukemia; Leukemia; Myelodysplastic Syndromes; Neoplasms; Melanoma; Breast Cancer; Metastatic Breast Cancer; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Renal Cell Carcinoma; Glioblastoma Multiforme; Osteosarcoma; Sarcoma; Thyroid Cancer; Genitourinary |
Celgene |
2014-10-27 | PHASE1 |
| NCT02750995 | COMPLETED | Myelodysplastic Syndrome; Acute Myeloid Leukemia |
Daniel El Fassi |
2016-04 | PHASE1 |
| NCT02323139 | COMPLETED | MDS |
Groupe Francophone des Myelodysplasies |
2015-02-10 | PHASE1 |
| NCT01983969 | COMPLETED | Advanced Cancers; Lymphoma |
M.D. Anderson Cancer Center |
2013-11-07 | PHASE1; PHASE2 |
| NCT01369368 | UNKNOWN | Acute Myeloid Leukemia |
University of Bergen |
2013-08 | PHASE1; PHASE2 |
| NCT02750254 | TERMINATED | Acute Myeloid Leukemia; Myelodysplastic Syndrome; Acute Lymphocytic Leukemia |
Washington University School of Medicine |
2016-06-27 | PHASE1 |
| NCT02269943 | COMPLETED | Nasopharyngeal Neoplasms |
Celgene |
2015-02-13 | PHASE2 |
| NCT01935947 | TERMINATED | Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer |
National Cancer Institute (NCI) |
2013-05 | PHASE2 |
| NCT02129101 | COMPLETED | Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Essential Thrombocythemia; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Polycythemia Vera; Previously Treated Myelodysplastic Syndrome; Primary Myelofibrosis; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia |
Mayo Clinic |
2014-05 | PHASE1 |
| NCT01957644 | TERMINATED | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic |
Boehringer Ingelheim |
2013-11-06 | PHASE1 |
| NCT02374099 | TERMINATED | Breast Neoplasms |
Celgene |
2015-03-13 | PHASE2 |
| NCT01913951 | COMPLETED | Myelodysplastic Syndromes |
Washington University School of Medicine |
2013-11-22 | PHASE1 |
| NCT01912274 | COMPLETED | Acute Myeloid Leukemia |
Helsinn Healthcare SA |
2013-12-24 | PHASE2 |
| NCT02341495 | TERMINATED | Acute Myeloid Leukemia |
Elizabeth Henry |
2013-02 | PHASE2 |
| NCT01093573 | COMPLETED | Untreated Adult Acute Myeloid Leukemia |
Brenda Cooper, MD |
2009-07 | PHASE1; PHASE2 |
| NCT02096042 | TERMINATED | Leukemia |
M.D. Anderson Cancer Center |
2014-04 | PHASE1; PHASE2 |
| NCT01814826 | COMPLETED | Acute Myelogenous Leukemia |
Millennium Pharmaceuticals, Inc. |
2013-04-10 | PHASE1 |
| NCT02158936 | TERMINATED | Thrombocytopaenia |
Novartis Pharmaceuticals |
2014-06-10 | PHASE3 |
| NCT01743859 | COMPLETED | Acute Myeloid Leukemia |
University of Colorado, Denver |
2012-12-06 | PHASE2 |
| NCT01067274 | WITHDRAWN | Acute Myeloid Leukemia |
Acute Leukemia French Association |
2010-04 | PHASE3 |
| NCT01617226 | COMPLETED | Leukemia, Myeloid, Acute |
University of Birmingham |
2012-09 | PHASE2 |
| NCT02260440 | COMPLETED | Metastatic Colorectal Cancer |
Anuradha Krishnamurthy |
2015-01 | PHASE2 |
| NCT02197676 | COMPLETED | MDS |
Groupe Francophone des Myelodysplasies |
2014-08-04 | PHASE2 |
| NCT02147873 | TERMINATED | Myelodysplastic Syndrome (MDS); Chronic Myelomonocytic Leukemia (CMML) |
TetraLogic Pharmaceuticals |
2014-06 | PHASE2 |
| NCT01168219 | COMPLETED | Acute Myeloid Leukemia; Adult Acute Megakaryoblastic Leukemia; Adult Acute Monoblastic Leukemia; Adult Acute Monocytic Leukemia; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With Maturation; Adult Acute Myeloid Leukemia With Minimal Differentiation; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL; Adult Acute Myeloid Leukemia Without Maturation; Adult Acute Myelomonocytic Leukemia; Adult Erythroleukemia; Adult Pure Erythroid Leukemia; Alkylating Agent-Related Acute Myeloid Leukemia; de Novo Myelodysplastic Syndrome; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts; Recurrent Adult Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome |
National Cancer Institute (NCI) |
2010-07-15 | PHASE2 |
| NCT01038635 | COMPLETED | Leukemia |
M.D. Anderson Cancer Center |
2009-12 | PHASE1; PHASE2 |
| NCT00934440 | TERMINATED | Renal Cell Carcinoma |
University of Kansas Medical Center |
2009-06 | PHASE1; PHASE2 |
| NCT00748553 | COMPLETED | Advanced or Metastatic Solid Tumors; Advanced or Metastatic Breast Cancer |
University of Utah |
2008-09 | PHASE1; PHASE2 |
| NCT01794169 | TERMINATED | Acute Myeloid Leukemia |
Karolinska University Hospital |
2013-03 | PHASE2 |
| NCT01908387 | TERMINATED | Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia; Multiple Myeloma; Non-Hodgkin Lymphoma; Hodgkin Lymphoma |
Celgene Corporation |
2013-07 | PHASE1 |
| NCT01202877 | COMPLETED | Leukemia |
M.D. Anderson Cancer Center |
2011-03 | PHASE1; PHASE2 |
| NCT02159040 | TERMINATED | High Risk MDS |
Novartis Pharmaceuticals |
2014-09-11 | PHASE2 |
| NCT00503984 | TERMINATED | Prostate Cancer; Pain |
University of Miami |
2007-05 | PHASE1; PHASE2 |
| NCT01828346 | COMPLETED | Myelodysplastic Syndrome |
TetraLogic Pharmaceuticals |
2013-06 | PHASE1; PHASE2 |
| NCT01358734 | COMPLETED | Acute Myeloid Leukemia; Acute Myelogenous Leukemia |
Celgene |
2012-04-27 | PHASE2 |
| NCT01993641 | COMPLETED | Myelodysplastic Syndrome; MDS |
Helsinn Healthcare SA |
2013-12 | PHASE2 |
| NCT00948064 | COMPLETED | Leukemia |
M.D. Anderson Cancer Center |
2009-09-08 | PHASE2 |
| NCT02204020 | WITHDRAWN | Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS) |
University of Pittsburgh |
2015-04 | PHASE2 |
| NCT01260714 | TERMINATED | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia; Adult Acute Monoblastic Leukemia; Adult Acute Monocytic Leukemia; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With Maturation; Adult Acute Myeloid Leukemia With Minimal Differentiation; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL; Adult Acute Myeloid Leukemia Without Maturation; Adult Acute Myelomonocytic Leukemia; Adult Erythroleukemia; Adult Pure Erythroid Leukemia; Alkylating Agent-Related Acute Myeloid Leukemia; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2010-12 | PHASE1 |
| NCT01886573 | TERMINATED | Stage IA Non-Small Cell Lung Carcinoma; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer |
National Cancer Institute (NCI) |
2013-06 | PHASE1 |
| NCT01599325 | COMPLETED | Myelodysplastic Syndrome (MDS) |
Celgene |
2012-07-24 | PHASE2 |
| NCT01545947 | COMPLETED | Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer |
Celgene |
2012-05-01 | PHASE1 |
| NCT01324960 | WITHDRAWN | Myelodysplastic Syndromes |
Groupe Francophone des Myelodysplasies |
2011-03 | PHASE1; PHASE2 |
| NCT00413478 | TERMINATED | Chronic Lymphocytic Leukemia; Leukemia |
M.D. Anderson Cancer Center |
2006-09 | PHASE2 |
| NCT00766116 | COMPLETED | Acute Myeloid Leukemia |
University of California, San Diego |
2005-07 | PHASE1; PHASE2 |
| NCT01350947 | COMPLETED | Chronic Myelomonocytic Leukemia |
University of Utah |
2011-04 | PHASE2 |
| NCT01050790 | COMPLETED | Multiple Myeloma |
Virginia Commonwealth University |
2010-01 | |
| NCT01861002 | COMPLETED | Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood |
Therapeutic Advances in Childhood Leukemia Consortium |
2013-05-22 | PHASE1 |
| NCT01065129 | COMPLETED | Myelodysplastic Syndromes |
Washington University School of Medicine |
2010-09-02 | PHASE1 |
| NCT00721214 | COMPLETED | Myelodysplastic Syndrome |
Virginia Commonwealth University |
2008-07 | PHASE2 |
| NCT00387465 | COMPLETED | Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer |
National Cancer Institute (NCI) |
2006-08 | PHASE1; PHASE2 |
| NCT01390311 | COMPLETED | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes |
Washington University School of Medicine |
2012-04 | PHASE1 |
| NCT01063257 | COMPLETED | Myelodysplastic Syndrome |
Groupe Francophone des Myelodysplasies |
2010-04 | PHASE1; PHASE2 |
| NCT01015352 | COMPLETED | Myelodysplastic Syndromes |
Groupe Francophone des Myelodysplasies |
2009-02 | PHASE2 |
| NCT01053806 | UNKNOWN | Myelodysplastic Syndrome |
Tel-Aviv Sourasky Medical Center |
2011-08 | PHASE2 |
| NCT01074047 | COMPLETED | Acute Myeloid Leukemia |
Celgene |
2010-06-01 | PHASE3 |
| NCT01167816 | TERMINATED | Pancreatic Cancer |
University of Oklahoma |
2010-07 | PHASE1 |
| NCT01016600 | COMPLETED | Leukemia, Myeloid, Acute |
Washington University School of Medicine |
2010-04 | PHASE1; PHASE2 |
| NCT01379274 | TERMINATED | MDS |
Rush University Medical Center |
2011-01 | PHASE2 |
| NCT00387647 | COMPLETED | Leukemia |
H. Lee Moffitt Cancer Center and Research Institute |
2006-08 | PHASE2 |
| NCT01748240 | TERMINATED | Myelodysplastic Syndrome |
Groupe Francophone des Myelodysplasies |
2013-03 | PHASE2 |
| NCT00911066 | COMPLETED | Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome |
Millennium Pharmaceuticals, Inc. |
2009-06 | PHASE1 |
| NCT00528983 | COMPLETED | Myelodysplastic Syndromes (MDS); Chronic Myelomonocytic Leukemia (CMML); Acute Myelogenous Leukemia (AML) |
Celgene |
2007-09-11 | PHASE1 |
| NCT01200004 | TERMINATED | Advanced Cancers |
M.D. Anderson Cancer Center |
2012-04 | PHASE1 |
| NCT00313586 | COMPLETED | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL; Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA; Alkylating Agent-Related Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome; Untreated Adult Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2006-08 | PHASE2 |
| NCT01535456 | TERMINATED | AML; MDS |
University of Wisconsin, Madison |
2012-07 | |
| NCT00895934 | COMPLETED | Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2009-05 | PHASE1; PHASE2 |
| NCT01813838 | TERMINATED | SMD |
Groupe Francophone des Myelodysplasies |
2013-06 | PHASE1; PHASE2 |
| NCT01110473 | COMPLETED | Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; B-cell Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Myelodysplasia |
AbbVie (prior sponsor, Abbott) |
2010-04 | PHASE1 |
| NCT01249430 | COMPLETED | Recurrent Adult Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2011-01-20 | PHASE1 |
| NCT01201811 | COMPLETED | Myelodysplastic Syndromes |
Celgene |
2010-10-01 | PHASE4 |
| NCT01481220 | COMPLETED | Myelodysplastic Syndrome; Thrombocytopenia |
Nordic MDS Group |
2011-10 | PHASE1 |
| NCT00336063 | ACTIVE_NOT_RECRUITING | Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Nasopharyngeal Undifferentiated Carcinoma; Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7; Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7 |
National Cancer Institute (NCI) |
2006-03-03 | PHASE1 |
| NCT00915785 | COMPLETED | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute |
King's College London |
2005-11 | PHASE2 |
| NCT01120834 | COMPLETED | Lymphoma |
Weill Medical College of Cornell University |
2010-09 | PHASE1; PHASE2 |
| NCT01121757 | TERMINATED | Follicular Lymphoma; Marginal Zone Lymphoma |
Duke University |
2010-04 | PHASE2 |
| NCT00351975 | COMPLETED | Accelerated Phase of Disease; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL; Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia; Previously Treated Myelodysplastic Syndrome; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Disease; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome |
National Cancer Institute (NCI) |
2006-06 | PHASE1 |
| NCT01519011 | COMPLETED | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute |
Celgene |
2012-02-07 | PHASE1 |
| NCT00915252 | COMPLETED | Acute Myeloid Leukemia |
University Hospital Muenster |
2009-07 | PHASE2 |
| NCT01152346 | COMPLETED | Myelodysplastic Syndrome |
Bioniche Pharma USA LLC |
2011-04 | PHASE1 |
| NCT00529022 | COMPLETED | Solid Tumors |
M.D. Anderson Cancer Center |
2007-08 | PHASE1 |
| NCT01039155 | COMPLETED | Adult Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm |
National Cancer Institute (NCI) |
2009-12 | PHASE1 |
| NCT01133886 | UNKNOWN | Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome |
King's College London |
2010-09 | PHASE2 |
| NCT00454480 | COMPLETED | Leukemia; Myelodysplastic Syndromes |
The University of New South Wales |
2006-08 | PHASE2; PHASE3 |
| NCT00923234 | TERMINATED | Myelodysplastic Syndromes; Acute Myelogenous Leukemia |
Technische Universität Dresden |
2009-06 | PHASE1 |
| NCT01180322 | COMPLETED | Acute Myeloid Leukemia (AML) |
University of Ulm |
2010-11 | PHASE2 |
| NCT01129180 | COMPLETED | Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Prolymphocytic Leukemia; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Small Intestine Lymphoma; T-cell Large Granular Lymphocyte Leukemia |
Pierluigi Porcu |
2010-05 | PHASE1 |
| NCT01453140 | TERMINATED | Graft Versus Host Disease |
Hackensack Meridian Health |
2011-08 | PHASE1; PHASE2 |
| NCT00901069 | COMPLETED | Lymphoma; Hodgkin Disease; Lymphoma, Non-Hodgkin |
Shams Shakil |
2009-05 | PHASE1 |
| NCT01305460 | COMPLETED | Myelodysplastic Syndrome |
Groupe Francophone des Myelodysplasies |
2011-07-05 | PHASE1; PHASE2 |
| NCT00352001 | COMPLETED | Leukemia; Myelodysplastic Syndromes |
Mikkael Sekeres MD |
2006-05 | PHASE1; PHASE2 |
| NCT01241786 | TERMINATED | Chronic Lymphocytic Leukemia(CLL); Small Lymphocytic Lymphoma |
Hackensack Meridian Health |
2010-07 | PHASE2 |
| NCT00996515 | COMPLETED | Advanced Solid Tumor Malignancies |
New Mexico Cancer Research Alliance |
2008-06 | PHASE1 |
| NCT00495547 | TERMINATED | Myelodysplastic Syndrome |
PETHEMA Foundation |
2009-02 | PHASE2 |
| NCT01305135 | COMPLETED | High Grade Myelodysplastic Syndrome Lesions |
Groupe Francophone des Myelodysplasies |
2010-12-30 | PHASE1; PHASE2 |
| NCT00890929 | COMPLETED | Acute Myeloid Leukemia (AML); Adult Acute Myeloblastic Leukemia |
Stanford University |
2009-04 | PHASE1; PHASE2 |
| NCT00101179 | COMPLETED | Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Leukemia; Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome |
National Cancer Institute (NCI) |
2004-11-03 | PHASE1 |
| NCT01281124 | COMPLETED | Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Non-Small Cell Cancer AJCC v7 |
National Cancer Institute (NCI) |
2011-01-12 | PHASE2 |
| NCT00842582 | WITHDRAWN | Ovarian Cancer |
Loyola University |
2009-02 | PHASE1 |
| NCT01011283 | TERMINATED | Myelodysplastic Syndromes |
Eisai Inc. |
2009-11 | PHASE4 |
| NCT00997243 | TERMINATED | Leukemia; Myelodysplastic Syndromes |
Alison Walker |
2009-11 | PHASE2 |
| NCT00704704 | UNKNOWN | Myelodysplastic Syndrome |
Tel-Aviv Sourasky Medical Center |
2008-09 | PHASE2 |
| NCT00446303 | TERMINATED | Leukemia, Myelocytic, Acute; Myelodysplastic Syndromes |
Groupe Francophone des Myelodysplasies |
2006-07 | PHASE2 |
| NCT00439673 | COMPLETED | Myelodysplastic Syndromes |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2007-05 | PHASE2 |
| NCT00728520 | UNKNOWN | Acute Myeloid Leukemia; Elderly |
Kansas City Veteran Affairs Medical Center |
2008-07 | PHASE2 |
| NCT00398450 | COMPLETED | Melanoma (Skin) |
University of California, San Diego |
2006-02 | PHASE1 |
| NCT00700011 | TERMINATED | Myelodysplastic Syndromes |
Texas Oncology Cancer Center |
2008-03 | PHASE2 |
| NCT00739388 | COMPLETED | Leukemia |
Swiss Cancer Institute |
2008-07 | PHASE2 |
| NCT00422890 | COMPLETED | Myeloid Leukemia; Myelodysplastic Syndrome |
Technische Universität Dresden |
2007-01 | PHASE3 |
| NCT00897130 | COMPLETED | Myelodysplastic Syndrome |
Università degli Studi di Brescia |
2008-08 | PHASE2 |
| NCT00321711 | COMPLETED | MDS; Myelodysplastic Syndromes; Thrombocytopenia |
Amgen |
2006-10-01 | PHASE2 |
| NCT00496444 | COMPLETED | Advanced Cancers |
M.D. Anderson Cancer Center |
2005-05 | PHASE1 |
| NCT00569010 | COMPLETED | Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Leukemia |
M.D. Anderson Cancer Center |
2005-12 | PHASE1; PHASE2 |
| NCT01186939 | COMPLETED | Myelodysplastic Syndromes |
Celgene |
2007-04-01 | PHASE3 |
| NCT00666497 | TERMINATED | Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS) |
Mirati Therapeutics Inc. |
2008-06 | PHASE2 |
| NCT00543582 | TERMINATED | Hodgkin Lymphoma; Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma) |
Mirati Therapeutics Inc. |
2007-10 | PHASE2 |
| NCT00234000 | TERMINATED | Leukemia; Myelodysplastic Syndromes |
Jonsson Comprehensive Cancer Center |
2007-02 | PHASE1 |
| NCT00379912 | TERMINATED | Myelodysplastic Syndromes |
Larry Cripe, MD |
2006-09 | PHASE2 |
| NCT00324220 | COMPLETED | Myelodysplastic Syndrome; Acute Myelogenous Leukemia |
Mirati Therapeutics Inc. |
2006-01 | PHASE1; PHASE2 |
| NCT00412919 | TERMINATED | Multiple Myeloma |
Bayside Health |
2006-12 | PHASE2 |
| NCT00102687 | COMPLETED | Myelodysplastic Syndromes |
Celgene |
2005-01-01 | PHASE2 |
| NCT00384956 | COMPLETED | Myelodysplastic Syndromes |
Washington University School of Medicine |
2006-08 | PHASE2 |
| NCT00217542 | COMPLETED | Recurrent Melanoma; Recurrent Renal Cell Cancer; Stage III Melanoma; Stage IV Melanoma; Stage IV Renal Cell Cancer |
National Cancer Institute (NCI) |
2005-07 | PHASE1 |
| NCT00339196 | COMPLETED | Acute Myelogenous Leukaemia (AML); Myelodysplastic Syndrome (MDS) |
Assistance Publique - Hôpitaux de Paris |
2006-07 | PHASE2 |
| NCT00443261 | TERMINATED | Squamous Cell Carcinoma |
University of Kansas Medical Center |
2007-02 | PHASE1 |
| NCT00569660 | COMPLETED | Myelofibrosis |
M.D. Anderson Cancer Center |
2005-06 | PHASE2 |
| NCT00381693 | TERMINATED | Chronic Myeloproliferative Disorders; Secondary Myelofibrosis |
Mayo Clinic |
2006-08 | PHASE2 |
| NCT00382590 | COMPLETED | Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Leukemia |
M.D. Anderson Cancer Center |
2005-08 | PHASE2 |
| NCT00071799 | COMPLETED | Myelodysplastic Syndromes |
Celgene |
2003-11-01 | PHASE3 |
| NCT00326170 | COMPLETED | Myelodysplastic Syndrome; Acute Myelogenous Leukemia |
M.D. Anderson Cancer Center |
2005-07 | PHASE2 |
| NCT00118196 | TERMINATED | Leukemia; Myelodysplastic Syndromes |
Medical University of South Carolina |
2005-04 | PHASE2 |
| NCT00005639 | COMPLETED | Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2000-03 | PHASE1 |
| NCT00005598 | COMPLETED | Myelodysplastic Syndromes |
University of Michigan Rogel Cancer Center |
2000-10 | PHASE2 |
| NCT00004062 | COMPLETED | Head and Neck Cancer |
Lucille P. Markey Cancer Center at University of Kentucky |
1999-07 | PHASE1 |
| NCT00004871 | COMPLETED | Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2000-05 | PHASE1 |
| NCT00005934 | COMPLETED | Beta Thalassemia |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2000-06 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-09-03)
Check the
5-Azacytidine (5-Aza, Azacitidine)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- 5-Azacytidine (5-Aza, Azacitidine) Mechanism of Action: DNMT Inhibition in Hematopoietic Stem Cell Research
- 5-Azacytidine (5-Aza, Azacitidine) Working Concentration | Cell Culture | Treatment
- 5-Azacytidine (5-Aza, Azacitidine) Solubility in DMSO
- 5-Azacytidine (5-Aza, Azacitidine) Stock Solution
- 5-Azacytidine (5-Aza, Azacitidine) Storage
- 5-Azacytidine (5-Aza, Azacitidine) Stability
- 5-Azacytidine (5-Aza, Azacitidine) Combination Database
- 5-Azacytidine (5-Aza, Azacitidine) Molecular Weight
- 5-Azacytidine (5-Aza, Azacitidine) SMILES
- 5-Azacytidine (5-Aza, Azacitidine) CAS Number
- 5-Azacytidine (5-Aza, Azacitidine) Chemical Structure (2D and 3D)
- 5-Azacytidine (5-Aza, Azacitidine) IC50 for Cell-based and Cell-free Assays
- 5-Azacytidine (5-Aza, Azacitidine) Sigma (A2385)? Try a better option.
- 5-Azacytidine (5-Aza, Azacitidine) MedChemExpress (HY-10586)? Try a better option.
- 5-Azacytidine (5-Aza, Azacitidine) Cayman (11164)? Try a better option.
- 5-Azacytidine (5-Aza, Azacitidine) Cell Signaling Technology (50646)? Try a better option.
- 5-Azacytidine (5-Aza, Azacitidine) Tocris (3842)? Try a better option.
- 5-Azacytidine (5-Aza, Azacitidine) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.